

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Duality Biotherapeutics, Inc.

映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock code: 9606)

VOLUNTARY ANNOUNCEMENT

ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB SHARES ON SCI-TECH BOARD

This announcement is made by Duality Biotherapeutics, Inc. (the “**Company**”) to provide its shareholders and potential investors with information in relation to the latest development regarding the Company.

Reference is made to the announcements of the Company dated October 17, 2025 and April 13, 2026 and the circular of the Company dated April 14, 2026, in respect of the proposed issue of ordinary shares to be listed and traded in RMB on the Science and Technology Innovation Board of the Shanghai Stock Exchange (the “**Proposed Listing**”).

The Company is currently receiving counselling from CITIC Securities Co., Ltd. and the Company has obtained the acceptance from the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission in respect of such counselling.

The Company will announce the progress of the Proposed Listing as and when appropriate according to applicable laws and rules.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Hong Kong, June 10, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.